Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
Anhui Huaheng Biotechnology Co., Ltd. (SHSE:688639) just released its latest second-quarter report and things are not looking great. Anhui Huaheng Biotechnology delivered a grave earnings miss, with both revenues (CN¥515m) and statutory earnings per share (CN¥0.40) falling badly short of analyst expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
安徽華恒生物技術股份有限公司(SHSE: 688639)剛剛發佈了最新的第二季度報告,情況不容樂觀。安徽華恒生物技術的收入(5.15億元人民幣)和每股收益(0.40元人民幣)都大大低於分析師預期,表現糟糕。盈利報告對投資者來說是重要的時刻,可以追蹤公司的表現,查看分析師對明年的預測,並觀察市場對該公司的情緒是否發生變化。因此,我們收集了最新的盈利後預測,看看未來一年的預期。
![1724971983054](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240830/43089362-0-959116956db1704b80a422d6adf3b0d7.webp/bigjpg)
Following the latest results, Anhui Huaheng Biotechnology's seven analysts are now forecasting revenues of CN¥2.82b in 2024. This would be a substantial 34% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 5.1% to CN¥1.88. Before this earnings report, the analysts had been forecasting revenues of CN¥3.17b and earnings per share (EPS) of CN¥2.77 in 2024. It looks like sentiment has declined substantially in the aftermath of these results, with a real cut to revenue estimates and a pretty serious reduction to earnings per share numbers as well.
根據最新的結果,安徽華恒生物技術的七位分析師預計2024年的收入將達到282億元人民幣。這將是過去12個月中營收大幅增長34%。預計每股收益將累積增長5.1%至1.88元人民幣。在此盈利報告之前,分析師們預測2024年的收入爲317億元人民幣,每股收益爲2.77元人民幣。看起來市場情緒在這些結果的影響下大幅下降,收入預測受到明顯減少,並且每股收益也大幅減少。
The consensus price target fell 23% to CN¥71.99, with the weaker earnings outlook clearly leading valuation estimates. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Anhui Huaheng Biotechnology at CN¥96.55 per share, while the most bearish prices it at CN¥43.56. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
共識價格目標下調23%至71.99元人民幣,明顯受到較弱的盈利前景的影響。但是,僅固定在一個價格目標上可能不明智,因爲共識目標實際上是分析師價格目標的平均值。因此,一些投資者喜歡查看估計範圍,以了解公司估值是否存在分歧意見。目前,最看好的分析師將安徽華恒生物技術的估值設定爲96.55元人民幣每股,而最看淡的則將其定價爲43.56元人民幣。這是一個相當廣泛的估計範圍,表明分析師對該企業的未來走勢有着廣泛的預期。
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Anhui Huaheng Biotechnology's rate of growth is expected to accelerate meaningfully, with the forecast 79% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 37% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 15% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Anhui Huaheng Biotechnology is expected to grow much faster than its industry.
當然,審視這些預測的另一種方式是將它們與行業本身的情況聯繫起來。從最新的估算結果來看,預計安徽華恒生物技術的增長率將加速,預計到2024年年化營業收入增長率將達到79%,明顯快於過去三年的歷史增長37%。相比之下,我們的數據表明,預計類似行業(受到分析師覆蓋)的其他公司將以每年15%的速度增長營業收入。考慮到營業收入的預測加速,很明顯安徽華恒生物技術的增長速度預計將遠遠快於其所在的行業。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Anhui Huaheng Biotechnology. They also downgraded Anhui Huaheng Biotechnology's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Anhui Huaheng Biotechnology's future valuation.
最大的擔憂是分析師們下調了每股收益的預估,表明安徽華恒生物技術可能面臨業務上的逆風。他們還下調了安徽華恒生物技術的營業收入預估,但行業數據顯示預計其增長速度將快於更廣泛的行業。共識價值目標明顯下降,分析師似乎對最新的結果不感到放心,導致對安徽華恒生物技術未來估值的預期降低。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Anhui Huaheng Biotechnology analysts - going out to 2026, and you can see them free on our platform here.
記住,我們仍然認爲業務的長期軌跡對於投資者來說更爲重要。我們有多位安徽華恒生物技術分析師的估算,覆蓋到2026年,你可以在我們的平台上免費查看。
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Anhui Huaheng Biotechnology (2 can't be ignored) you should be aware of.
不要忘記,可能仍然存在風險。例如,我們已經找到了安徽華恒生物技術的3個警示信號(其中2個不容忽視),你應該注意。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。